Budesonide oral suspension improved histologic, endoscopic, and both histologic and symptomatic outcomes in children with eosinophilic esophagitis compared with placebo.
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children.
Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. And as ever, one final movie trivia ‘guess the quote’ to end the year!
The FDA has accepted for review the NDA and granted Priority Review to TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.
Topical glucocorticosteroids recommended over no treatment.
Mylan has announced a recall of 3 lots of Nizatidine Capsules as the products were manufactured with an active pharmaceutical ingredient (API) that contained trace amounts of N-nitrosodimethylamine (NDMA), a probable human carcinogen.
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
A recently published report describes the case of a patient who experienced severe drug-induced esophagitis and highlights the importance of being aware of this phenomenon, as well as the strategies that may be used to manage it. The patient, a 77-year-old male, presented to the emergency department (ED) complaining of severe epigastric and retrosternal pain…
Budesonide oral suspension was associated with improvements in dysphagia in patients with eosinophilic esophagitis.
